콜레스테롤 저하제 시장 : 질환별, 약효군별, 유통채널별 - 세계 예측(2025-2030년)

The Cholesterol Lowering Drug Market was valued at USD 22.00 billion in 2023, expected to reach USD 23.80 billion in 2024, and is projected to grow at a CAGR of 8.30%, to USD 38.45 billion by 2030.

The market for cholesterol-lowering drugs is a vital segment of the pharmaceutical industry, focusing on medications designed to reduce cholesterol levels in the blood, primarily targeting LDL cholesterol, to prevent cardiovascular diseases. The necessity for such drugs is underscored by the global rise in cholesterol-related conditions, driven by lifestyle factors such as poor diet, lack of exercise, and an aging population. Their application ranges from preventive treatments for at-risk individuals to interventions for those with existing cardiovascular issues, with end-users including hospitals, clinics, and individuals managing chronic conditions. Growth in this market is primarily influenced by the increasing prevalence of hypercholesterolemia, an expanding geriatric population, and heightened awareness of heart health.

However, limitations such as high costs of branded medications, potential side effects, and medication adherence challenges can hinder market expansion. Moreover, the growing popularity of alternative therapies and lifestyle-based interventions presents a competitive challenge. Despite these obstacles, potential opportunities lie in the development of novel biologics and biosimilars, personalized medicine approaches, and expanding markets in emerging economies where healthcare access is improving. To seize these opportunities, pharmaceutical companies are advised to invest in R&D for next-generation cholesterol-lowering agents and leverage data analytics to develop personalized treatment plans.

Innovation could focus on combination therapies that address multiple cardiovascular risk factors, as well as digital health technologies that assist in patient monitoring and adherence. Research into gene therapy and nutraceuticals also offers promising avenues for breakthrough treatments. The nature of the market is increasingly competitive yet ripe with potential, driven by unmet medical needs and technological advancements. Collaborations between biotech firms and research institutions could further enhance drug discovery processes, while strategic alliances with healthcare providers could improve patient engagement and market penetration.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cholesterol Lowering Drug Market

The Cholesterol Lowering Drug Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising burden of LDL cholesterol across the globe
  • Growing geriatric population with cholesterol complications
  • Increase in smoking and alcohol consumption escalate the risk of high cholesterol
• Market Restraints
  • Severe side effects of statins causing rhabdomyolysis
• Market Opportunities
  • Government investment toward the strengthening healthcare infrastructure
  • Development of drug formulation and emergence of new therapies such as emergence of PCSK9 inhibitors
• Market Challenges
  • Availability of generic drugs of leading brands and stringent approvals process

Porter's Five Forces: A Strategic Tool for Navigating the Cholesterol Lowering Drug Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cholesterol Lowering Drug Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cholesterol Lowering Drug Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cholesterol Lowering Drug Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cholesterol Lowering Drug Market

A detailed market share analysis in the Cholesterol Lowering Drug Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cholesterol Lowering Drug Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cholesterol Lowering Drug Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cholesterol Lowering Drug Market

A strategic analysis of the Cholesterol Lowering Drug Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cholesterol Lowering Drug Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Anant Pharmaceuticals Pvt. Ltd., AstraZeneca PLC, Bristol-Myers Squibb Company, Covis Pharma GmbH, Daiichi Sankyo Co., Ltd., Dr. Reddy's Laboratories Ltd., Kowa Company, Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Cholesterol Lowering Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Disease Type, market is studied across Cardiovascular Diseases, Hypercholesterolemia, and Hyperlipidemia.
• Based on Class of Drug, market is studied across Cholesterol Absorption Inhibitors, Fibrates, Fixed-Dose Combinations, Ion Exchange Resins, Novel Cholesterol-Lowering Drugs, PCSK9 Inhibitors, and Statins.
• Based on Distribution Channels, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising burden of LDL cholesterol across the globe
    • 5.1.1.2. Growing geriatric population with cholesterol complications
    • 5.1.1.3. Increase in smoking and alcohol consumption escalate the risk of high cholesterol
  • 5.1.2. Restraints
    • 5.1.2.1. Severe side effects of statins causing rhabdomyolysis
  • 5.1.3. Opportunities
    • 5.1.3.1. Government investment toward the strengthening healthcare infrastructure
    • 5.1.3.2. Development of drug formulation and emergence of new therapies such as emergence of PCSK9 inhibitors
  • 5.1.4. Challenges
    • 5.1.4.1. Availability of generic drugs of leading brands and stringent approvals process
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cholesterol Lowering Drug Market, by Disease Type

• 6.1. Introduction
• 6.2. Cardiovascular Diseases
• 6.3. Hypercholesterolemia
• 6.4. Hyperlipidemia

7. Cholesterol Lowering Drug Market, by Class of Drug

• 7.1. Introduction
• 7.2. Cholesterol Absorption Inhibitors
• 7.3. Fibrates
• 7.4. Fixed-Dose Combinations
• 7.5. Ion Exchange Resins
• 7.6. Novel Cholesterol-Lowering Drugs
• 7.7. PCSK9 Inhibitors
• 7.8. Statins

8. Cholesterol Lowering Drug Market, by Distribution Channels

• 8.1. Introduction
• 8.2. Hospital Pharmacies
• 8.3. Online Pharmacies
• 8.4. Retail Pharmacies

9. Americas Cholesterol Lowering Drug Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Cholesterol Lowering Drug Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Cholesterol Lowering Drug Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Amgen Inc.
• 2. Anant Pharmaceuticals Pvt. Ltd.
• 3. AstraZeneca PLC
• 4. Bristol-Myers Squibb Company
• 5. Covis Pharma GmbH
• 6. Daiichi Sankyo Co., Ltd.
• 7. Dr. Reddy's Laboratories Ltd.
• 8. Kowa Company, Ltd.
• 9. Merck & Co., Inc.
• 10. Novartis AG
• 11. Pfizer Inc.
• 12. Sanofi
• 13. Sun Pharmaceutical Industries Ltd.
• 14. Teva Pharmaceutical Industries Ltd.
• 15. Viatris Inc.